ARGX Price Prediction Next Week
Technical Analysis
Based on the technical indicators, ARGX is currently showing mixed signals. The RSI-14 at 55.68 indicates a neutral momentum, neither overbought nor oversold. The stock is trading above both its 20-day moving average ($642.71) and 60-day moving average ($614.90), suggesting a generally positive trend.
Price Levels and Support/Resistance
Key price levels identified through Fibonacci analysis:
- Resistance levels: R1: $672.41, R2: $682.40, R3: $698.59
- Support levels: S1: $640.04, S2: $630.04, S3: $613.86
- Pivot point: $656.22
News Sentiment Analysis
Recent positive catalysts include:
- Multiple analyst upgrades with bullish price targets:
- JMP Securities: $696 price target
- Goldman Sachs: $813 price target
- Bank of America: $761 price target
The company recently reported preliminary Q4 revenue of $737M, significantly beating consensus of $627.99M. For FY24, Argenx sees revenue of $2.2B, above consensus of $2.01B.
Price Prediction for Next Week
Based on the technical setup and recent momentum:
- Expected trading range: $633.48 - $664.40
- Most likely scenario: Bullish movement toward $665-670 range
- Key resistance to watch: $672.41
- Stop-loss level recommended: $626.17
Trading Recommendation
BUY with the following strategy:
- Entry point: Current level ($648.94)
- Target: $672.41 (First resistance level)
- Stop loss: $626.17
- Risk/Reward ratio: 1:1.8
The recommendation is based on:
- Strong fundamental backdrop with better-than-expected Q4 results
- Multiple positive analyst upgrades
- Trading above key moving averages
- Clear technical support levels for risk management
The stock shows potential for upward movement given the positive revenue outlook and analyst sentiment, while technical indicators suggest a favorable risk-reward setup for a long position.
ARGX Similar Chart Price Prediction
The price of ARGX is predicted to go up 6.48%, based on the high correlation periods with ELS. The similarity of these two price pattern on the periods is 95.86%.
ARGX
ELS
Up: 6.48%Similarity: 95.86%
ARGX Revenue Forecast
ARGX EPS Forecast
ARGX FAQs
What is revenue forecast for next quarter？
What is eps forecast for next quarter？
ARGX VS S&P500
Novel FcRn inhibitor Vyvgart is a pipeline in a product, currently approved in myasthenia gravis but in testing in multiple additional indications.
Vyvgart's approval in myasthenia gravis made it the first-to-market FcRn-targeting drug, putting Argenx in a strong position to entrench itself in the market before competitors arrive.
With exclusive access to Halozyme's subcutaneous drug delivery technology, Argenx can improve the convenience of Vyvgart and potentially differentiate its drug from future competition.
ARGX Analyst's Forecast
Joon Lee
Truist Securities
Strong Buy
Price Target
$660 → $700
Upside
+5.14%
Truist raised the firm's price target on Argenx to $700 from $660 and keeps a Buy rating on the shares. The company's Q4 revenue guidance was materially ahead of consensus estimates, while its 2025 R&D and SG&A guidance of $2.5BN against growing topline puts Argenx on a continued path to profitability, the analyst tells investors in a research note. At current trajectory, Argenx remains well poised to not only achieve but likely exceed "Vision 2030", and the stock is seen as one of Truist's "favorite names for 2025", the firm adds.
Jason Butler
JMP Securities
Buy
Price Target
$606 → $696
Upside
+4.53%
Derek Archila
Wells Fargo
Buy
Price Target
$639 → $723
Upside
+15.46%